The complex effects of heparins on cancer progression and metastasis in experimental studies

Pharmacological Reviews

Volumn 53, Issue 1, 2001, Pages 93-105

  Smorenburg, Susanne M ^a,b   Van Noorden, Cornelis J F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD1 ANTIGEN; CD11 ANTIGEN; COMPLEMENT COMPONENT C5A; FIBRIN; GELATINASE A; GELATINASE B; HEPARIN; HEPARIN DERIVATIVE; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; LAMININ; LOW MOLECULAR WEIGHT HEPARIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; RANTES; STROMELYSIN; THROMBIN; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; VASCULOTROPIN;

CANCER GRAFT; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; ENDOTHELIUM CELL; HUMAN; IMMUNOMODULATION; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 0035109328     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (237)

1. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
2. Role of integrins and other cell adhesion molecules in tumor progression and metastasis
3. Binding of two growth factor families to separate domains of the proteoglycan betaglycan
4. Low-dose heparin treatment does not inhibit SW480 human colon cancer growth and metastasis in vivo
5. In vitro effects of heparin on SW480 tumor cell-matrix interaction
6. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice
7. Expression of laminin and type IV collagen by basement membrane-producing EHS tumors in streptozotocin-induced diabetic mice: In vivo modulation by low-molecular-weight heparin fragments
8. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration
9. Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells
10. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation
11. Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface
12. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis
13. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis
14. Evaluation of cortisone-heparin and cortisone-maltose tetrapalmitate therapies against rodent tumors. I. Biological studies
15. Insight into the profibrinolytic activity of heparin: Effects on the activation of plasminogen mediated by urokinase
16. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins
17. Combined immunostimulation (Propionibacterium avidum KP 40) and anticoagulation (heparin) prevents metastatic lung and liver colonization in mice
18. Low-molecular weight heparins in venous and arterial thrombotic disease
19. Action of heparin and plasminogen inhibitor (EACA) on metastatic tumour spread in an isologous system
20. Effect of heparin and plasminogen inhibitor (EACA) in brief and prolonged treatment on intravenously injected tumour cells
21. Role of tissue factor in metastasis: Functions of the cytoplasmic and extracellular domains of the molecule
22. Role of integrins in angiogenesis
23. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation
24. Leukocyte-endothelial adhesion molecules
25. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells
26. Increased expression of alpha IIb beta 3 integrin in subpopulations of murine melanoma cells with high lung-colonizing ability
27. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin
28. Role of tumor cytoskeleton and membrane glycoprotein IRGpIIb/IIIa in platelet adhesion to tumor cell membrane and tumor cell-induced platelet aggregation
29. Factors affecting the development of metastatic cancer
30. Irradiation and anticoagulant therapy to prevent pulmonary metastases of the V2 carcinoma in rabbits
31. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin
32. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery
33. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor
34. The effects of unfractionated and low molecular weight heparins on microvascular endothelial cell proliferation and formation of capillary-like tubular structures in a fibrin matrix
35. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia
36. Analysis of the inhibition of tumour metastasis by sulphated polysaccharides
37. Fibrin and cancer
38. Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo
39. Regulation of tumor cell invasion by extracellular matrix
40. Heparin-endothelial cell interactions
41. Capillary growth: A two-cell system
42. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: Role of platelet glycoproteins P-selectin and GPIIb-IIIA
43. Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells
44. Effects of TGF-beta on the immune system: Implications for cancer immunotherapy
45. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
46. Anti-tumor and anti-angiogenic effects in mice of heparin conjugated to angiostatic steroids
47. ICAM-1 (CD54): A counter-receptor for Mac-1 (CD11b/CD18)
48. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1)
49. Angiogenesis: An update
50. Microvascular pericytes: A review of their morphological and functional characteristics
51. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma
52. Heparanase: Breaking down barriers in tumors
53. Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions
54. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion
55. Experimental studies of factors which influence hepatic metastases. VIII. Effect of anticoagulants
56. Angiogenesis and angiogenesis inhibition: An overview
57. A heparin-binding angiogenic protein-basic fibroblast growth factor is stored within basement membrane
58. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone
59. Control of angiogenesis with synthetic heparin substitutes
60. x as a new tumor-associatod antigen
61. + T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta
62. Influence of heparin(s) on the interleukin-1-beta-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts
63. Cancer cell procoagulants and their implications
64. Non-tissue factor procoagulants in cancer cells
65. Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue
66. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice
67. Role of NK cells in the antimetastatic effect of anticoagulant drugs
68. Laboratory diagnosis of the thrombophilic state in cancer patients
69. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
70. Role of tumor cell glycoproteins immunologically related to glycoproteins Ib and IIb/IIIa in tumor cell-platelet and tumor cell-matrix interactions
71. Effect of heparin, epsilon-aminocaproic acid and coumarin on tumour growth and spontaneous metastasis formation
72. Effect of heparin, coumarin and ε-aminocaproic acid (EACA) on spontaneous metastasis formation. Influence on the moment of metastasis formation. Possible cytotoxic effect of heparin and coumarin in blood
73. Tumour growth and spontaneous metastasis spread in two syngeneic systems
74. Disseminating effect of heparin on experimental tumour metastases
75. Distribution of intravenously induced metastases in heparin- and coumarin-treated mice
76. Evidence for effects of heparin on cell surfaces influencing experimental metastases
77. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Le(a) and sialosyl-Le(x), and sulfated glycans modulate this binding
78. Complement inhibitory and anticoagulant activities of fractionated heparins
79. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
80. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
81. Lipoxygenase products regulate IRGpIIb/IIIa receptor mediated adhesion of tumor cells to endothelial cells, subendothelial matrix and fibronectin
82. Alpha IIb beta 3 integrin expression and function in subpopulations of murine tumors
83. Platelets and cancer metastasis: A causal relationship?
84. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies
85. Integrins and health
86. Human transforming growth factor beta.alpha 2-macroglobulin complex is a latent form of transforming growth factor beta
87. Heparin inhibits endothelin-1 and protooncogene c-fos gene expression in cultured bovine endothelial cells
88. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells
89. Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix
90. Heparin effects on superoxide production by neutrophils
91. Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction
92. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells
93. The high affinity heparin-binding domain and the V region of fibronectin mediate invasion of human oral squamous cell carcinoma cells in vitro
94. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells
95. Tumor progression and angiogenesis: Cathepsin B & Co.
96. Structural changes in the NH2-terminal domain of fibronectin upon interaction with heparin. Relationship to matrix-driven translocation
97. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents
98. Mechanism of blood-borne metastases. I. Some factors affecting lodgment and growth of tumor cells in the lungs
99. Independence of metastatic ability and extravasation: Metastatic ras-transformed and control fibroblasts extravasate equally well
100. Matrix metalloproteinases and their inhibitors
101. Spatial and temporal expression of angiogenic molecules during tumor growth and progression
102. Immunohistochemical study of sialyl Le(a) and sialyl Le(x) antigen in oral squamous cell carcinoma: The association of sialyl Le(a) expression with the metastatic potential
103. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic anti-tumor and anti-metastatic properties
104. The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes
105. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin
106. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid
107. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone
108. Regulation of signal transduction and signal diversity by receptor oligomerization
109. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization
110. Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules
111. Identification of novel heparin-binding domains of vitronectin
112. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro
113. Cancer cell invasion and metastasis
114. Interactions between fibrin, collagen and endothelial cells in angiogenesis
115. Hepatocyte growth factor/scatter factor: A heparan sulphate-binding pleiotropic growth factor
116. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific
117. Extrapulmonary colony formation after intravenous injection of tumour cells into heparin-treated animals
118. Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems
119. Evaluation of cortisone-heparin and cortisone-maltoso tetrapalmitate therapies against rodent tumors. II. Pathological studies
120. Modulation of haptotactic migration of metastatic melanoma cells by the interaction between heparin and heparin-binding domain of fibronectin
121. The ins and outs of fibroblast growth factors
122. Transforming growth factor-beta
123. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex
124. RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and -independent activities
125. Selectins
126. Biology and biochemistry of proteinases in tumor invasion
127. Plasminogen activators and matrix metalloproteinases in angiogenesis
128. Treatment with cortisone plus heparin or hexuronyl hexoaminoglycan sulfates of murine tumors and their lung deposits
129. Heparin inhibits mitogen-activated protein kinase-dependent and -independent c-fos induction in mesangial cells
130. Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells
131. Role of integrins in cancer: Survey of expression patterns
132. Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy
133. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice
134. The role of plasminogen activators in the regulation of connective tissue metalloproteinases
135. Treatment of experimental liver metastases in the rat by continuous intraportal infusion of 5-fluorouracil and heparin; A pilot study
136. Heparanases and tumor metastasis
137. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer
138. The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration
139. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
140. Gene expression and protein deposition of major basement membrane components and TGF-beta 1 in human breast cancer
141. Matrix-driven translocation: Dependence on interaction of amino-terminal domain of fibronectin with heparin-like surface components of cells or particles
142. Cancer cell heparanase activity associated with invasion and metastasis
143. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo
144. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo
145. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells
146. Heparin and angiogenesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically
147. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin
148. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis
149. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
150. Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin
151. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma
152. Role of extracellular matrix on colonic cancer cell migration and proliferation
153. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells
154. Anticoagulant treatment of rats with Walker 256 carcinosarcoma
155. Localization of the heparin-binding site on complement factor H
156. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-coll-derived heparanases
157. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity
158. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
159. Combination heparin plus cortisone treatment of two transplanted tumors in C3H/He mice
160. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin
161. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
162. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form
163. Modulation of growth of melanoma
164. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells
165. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells
166. Stimulation of collagenase (matrix metalloproteinase-1) synthesis in histiotypic epithelial cell culture by heparin is enhanced by keratinocyte growth factor
167. Metalloproteases and urokinase in angiogenesis and tumor progression
168. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
169. Sialyl-Lewis(x/a)-decorated selectin ligands in head and neck tumours
170. Complement activation by interaction of polyanions and polycations. I. Heparin-pretamine induced consumption of complement
171. The effect of heparin on primary tumors and metastases
172. Exogenous heparin induces fibronectin overexpression parallel to angiogenesis in the extracellular matrix of the chick embryo chorioallantoic membrane
173. Hemostatic alterations in cancer patients
174. Regulation of angiogenesis by scatter factor
175. Key role of chemokines and chemokine receptors in inflammation, immunity, neoplasia, and infectious disease
176. Tissue factor in cancer angiogenesis and metastasis
177. Proteoglycans as modulators of growth factor activities
178. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization
179. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells
180. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma
181. Effect of angiostatic steroid with or without glucocorticoid activity on metastasis
182. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation
183. Serum sialyl Lewis X-i antigen levels in non-small cell lung cancer: Correlation with distant metastasis and survival
184. Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?
185. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis
186. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
187. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival
188. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
189. Small heparin fragments regulate the amplification pathway of complement
190. Interaction of endothelial cells and fibroblasts with modified fibrin networks: Role in atherosclerosis
191. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer
192. Purification and complete primary structures of the heparin-, cell-, and DNA-binding domains of bovine plasma fibronectin
193. PMN adhesion and extravasation as a paradigm for tumor cell dissemination
194. alpha2-macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver
195. The effects of unfractionated heparin on survival in patients with malignancy - A systematic review
196. Should patients with venous thromboembolism and cancer be treated differently?
197. In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis
198. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors
199. Stimulation of cell surface plasminogen activation by heparin and related polyionic substances
200. Heparin binding to the urokinase kringle domain
201. Inhibitive effect of heparin and dextran sulfate on experimental pulmonary metastases
202. Localization of heparin binding activity in recombinant laminin G domain
203. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes
204. Rapid induction of hepatocyte growth factor by heparin
205. Therapy of spontaneously metastatic HSV-2 induced hamster tumours with cortisone acetate administered with or without heparin
206. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors
207. Heparin-steroid conjugates: New angiogenesis inhibitors with antitumor activity in mice
208. Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various cell types
209. Role of alphaII(b)beta3 integrin in prostate cancer metastasis
210. The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells
211. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation
212. High levels of transforming growth factor beta 1 in patients with colorectal cancer: Association with disease progression
213. Heparin in inflammation: Potential therapeutic applications beyond anticoagulation
214. Role of fibrin and plasminogen activators in repair-associated angiogenesis: In vitro studies with human endothelial cells
215. Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B
216. Metastasis
217. Modulation of neovascularization and metastasis by species of heparin
218. Inhibition of tumor metastasis by heparanase inhibiting species of heparin
219. The role of thrombin in tumor cell metastasis
220. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells
221. Effect of heparin on mesangial cell growth and gene expression of matrix proteins
222. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8
223. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin
224. Heparin and modified heparin inhibit complement activation in vivo
225. Cell adhesion molecules: A critical examination of their role in metastasis
226. Regulation of matrix metalloproteinase expression in tumor invasion
227. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
228. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface
229. Mechanisms of metastasis production by blood-borne cancer cells
230. General mechanisms of metastasis
231. Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: A tumor-specific marker?
232. Heparin induces rapid and remarkable elevation of hepatocyte growth factor/scatter factor during trans arterial embolization of renal cell carcinoma
233. Role of the heparin-binding domain of chimeric peptides derived from fibronectin in cell spreading and motility
234. Identification of a heparin binding site and the biological activities of the laminin alpha1 chain carboxy-terminal globular domain
235. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice
236. Effects of cortisone with and without heparin on angiogenesis induced by prostaglandin E1 and by S180 cells, and on growth of murine transplantable tumours
237. Extracellular matrix modulates expression of growth factors and growth-factor receptors in liver-colonizing colon-cancer cell lines